Non-Small Cell Lung Cancer

New Drug: Repotrectinib for ROS1-fusion positive NSCLC

2024-06-21

  • Study

    Phase 1-2 single-arm (TRIDENT-1)
    ROS1-fusion positive advanced NSCLC
    TKI-naive (n=71) – prior-TKI (n=56)

  • Efficacy

    ORR: 79% and 38%
    mDoR: 34.1 mos and 14.8 mos
    mPFS: 35.7 mos and 9 mos
    59% of pts with ROS1 G2032R responded

  • Safety

    Most common AEs: Dizziness (58%), dysgeusia (50%), paresthesia (30%)


    • N Engl J Med 2024;390:118-131

    Drilon A Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

    http://doi.org/10.1056/NEJMoa2302299

    Reviewed by Ulas D. Bayraktar, MD on Jun 21, 2024